Provenance Record

Comprehensive biotech/medicine news article on FDA approval of Decnupaz for BPDCN. Well-structured with disease background, trial data, safety, regulatory history, and investigator quotes. 825 words fits News category.

source-0.html.gz (PR Newswire): confirmed approval date May 27 2026, 69.7% CR/CRc rate, 39.4% SCT rate, 9.7 months DOR, October 2020 BTD, both investigator quotes verbatim, boxed warning, adverse events. source-1.html.gz (AbbVie news): confirmed both quotes verbatim, trial data. source-2.html.gz (ONS): confirmed 0.045 mg/kg dosing every 3 weeks over 15-30 minutes, 51 R/R patients, 15.7% CR/CRc, 9.2 months DOR, 24.1 months follow-up, 11.8% SCT rate in R/R. source-3.html.gz (StockTitan): confirmed trial data and quotes. source-4 (AllSci): HTTP 403 - cannot verify AllSci-attributed claims: (1) mechanism description 'indolinobenzodiazepine pseudodimer payload that alkylates DNA, causing single-strand breaks without crosslinking' and (2) ImmunoGen acquisition for $10.1 billion in November 2023. Note: PR Newswire (source-0) confirms the DNA single-strand break mechanism, partially corroborating claim 1; the ImmunoGen acquisition price is widely documented public record. source-5.html.gz (Elzonris): confirmed 8-14 months median OS, 60s/70s age, skin lesions in ~90%. source-6.html.gz (NCBI StatPearls): confirmed tagraxofusp 2018 FDA approval, BPDCN disease characteristics. Note: StatPearls describes tagraxofusp as 'recombinant human interleukin-3 fused to a truncated diphtheria toxin' - the article's claim it 'works by inhibiting protein synthesis' is not explicitly stated in this snapshot but is consistent with diphtheria toxin's known mechanism.

Core clinical data all verified. Two AllSci-attributed claims unverifiable due to 403 block: (1) the specific chemical name 'indolinobenzodiazepine pseudodimer' (mechanism substance is corroborated by PR Newswire); (2) '$10.1 billion' and 'November 2023' for ImmunoGen acquisition (widely known but not in available snapshots). These are subordinate body claims, not in headline or lead. APPROVE_WITH_CORRECTIONS is appropriate.

High-quality FDA approval coverage with strong trial data. Two unverifiable AllSci-attributed specifics warrant a corrections note. Overall factually sound and well-sourced.